S&P Futures
4,064.00 -11.50 (-0.28%) Dow Futures
33,995.00 -28.00 (-0.08%) Nasdaq Futures
12,039.75 -67.00 (-0.55%) Russell 2000 Futures
1,906.00 -4.50 (-0.24%) Crude Oil
81.33 +0.32 (+0.40%) Gold
1,924.50 -5.50 (-0.28%)
Vanguard Funds PLC - Vanguard ESG Global Corporate Bond UCITS ETF (V3GE.F)
| Previous Close | 4.2467 |
| Open | 4.2131 |
| Bid | 4.2105 x N/A |
| Ask | 4.2652 x N/A |
| Day's Range | 4.2131 - 4.2131 |
| 52 Week Range | 3.9363 - 4.8874 |
| Volume | |
| Avg. Volume | 0 |
| Net Assets | N/A |
| NAV | 4.23 |
| PE Ratio (TTM) | N/A |
| Yield | 2.51% |
| YTD Daily Total Return | 3.34% |
| Beta (5Y Monthly) | 0.00 |
| Expense Ratio (net) | 0.15% |
| Inception Date | 2021-05-20 |
- GlobeNewswire
Basilea announces approval for additional formulation of antifungal Cresemba® (isavuconazole) in China
Chinese National Medical Products Administration (NMPA) granted Drug Approval License to Basilea’s license partner, Pfizer Inc.Intravenous use of Cresemba approved for the treatment of adult patients with invasive aspergillosis and invasive mucormycosis following previous approval of oral dosage form Basel/Allschwil, Switzerland, June 24, 2022 Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company, announced today that its license partner, Pfizer Inc. (NYSE: PFE, “P
- GlobeNewswire
Cresemba® sales in Asia Pacific region trigger sales milestone payment to Basilea from Pfizer
Basel/Allschwil, Switzerland, June 17, 2022 Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company, announced today that the sales of the antifungal Cresemba® (isavuconazole) by its license partner Pfizer Inc. (NYSE: PFE, “Pfizer”) in the Asia Pacific region, exceeded the threshold triggering the first sales milestone payment for this region of USD 1.25 million. David Veitch, Basilea’s Chief Executive Officer, stated: “We are very pleased with the commercial progress
